| A423 |
Ezabenlimab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Featured
|
Ezabenlimab (BI-754091) is an anti-PD-1 mAb with binding constant Kd value of 6 nM (CHO cells). Ezabenlimab blocks the interaction of PD-1 with PD-L1 and PD-L2. Ezabenlimab increases interferon-γ secretion in T cells, and inhibits tumor growth in vivo. |
|
| A424 |
Serplulimab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Featured
|
Serplulimab (HLX 10) is humanized monoclonal anti-PD-1 antibody. Serplulimab can be used in research of small cell lung cancer. |
|
| A425 |
Penpulimab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
Featured
|
Penpulimab is an IgG1 backbone anti-PD-1 monoclonal antibody with antitumor activities. |
|
| A426 |
Balstilimab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibod)
Featured
|
Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody against PD-1. |
|
| A427 |
UCB patent anti-PD-1 Biosimilar（Anti-PDCD1 / PD-1 / CD279 Reference Antibody）
Featured
|
|
|
| A428 |
MOR-8457 Biosimilar（Anti-PDGFB Reference Antibody）
Featured
|
|
|
| A429 |
Thrombogenics patent anti-PDGF-C Biosimilar（Anti-PDGFC / VEGFE Reference Antibody）
Featured
|
|
|
| A430 |
Olaratumab Biosimilar（Anti-PDGFRA / CD140a Reference Antibody）
Featured
|
Olaratumab (IMC-3G3; LY3012207) is an anti-platelet-derived growth factor receptor alpha (PDGFRα) human monoclonal IgG1 antibody with antitumor activity. |
|
| A431 |
Tovetumab Biosimilar（Anti-PDGFRA / CD140a Reference Antibody）
Featured
|
Tovetumab (MEDI-575) is an anti-PDGFRα monoclonal antibody that selectively blocks the PDGFRα signal transduction. Tovetumab can be used in the research of glioblastoma and non-small cell lung cancer (NSCLC). |
|
| A432 |
IMC-2C5 Biosimilar（Anti-PDGFRB / CD140b Reference Antibody）
Featured
|
|
|
| A433 |
Novo Nordisk patent anti-PGLYRP1 Biosimilar（Anti-PGLYRP1 / PGRP-S Reference Antibody）
Featured
|
|
|
| A434 |
Bavituximab Biosimilar（Anti-Phosphatidylserine Reference Antibody）
Featured
|
Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a phosphatidylserine (PS)-targeting monoclonal antibody, suppresses tumor growth by targeting tumor vasculature and reactivating antitumor immunity. Bavituximab plus Paclitaxel (HY-B0015) and Carboplatin (HY-17393), have enhanced inhibition on non-small-cell lung cancer. |
|
| A435 |
ATH3G10 Biosimilar（Anti-Phosphorylcholine Reference Antibody）
Featured
|
|
|
| A436 |
Diaccurate patent anti-sPLA2-GIB Biosimilar(Anti-PLA2G1B Reference Antibody)
Featured
|
|
|
| A437 |
ATN-658 Biosimilar（Anti-PLAUR / uPAR / CD87 Reference Antibody）
Featured
|
|
|
| A438 |
Genentech anti-PMEL17 Biosimilar（Anti-PMEL Reference Antibody）
Featured
|
|
|
| A439 |
Novartis patent anti-PMEL17 Biosimilar(Anti-PMEL Reference Antibody)
Featured
|
|
|
| A440 |
Genentech patent anti-Polyubiquitin Biosimilar(Anti-Polyubiquitin Reference Antibody)
Featured
|
|
|
| A441 |
Eureka patent anti-PRAME Biosimilar(Anti-PRAME Reference Antibody)
Featured
|
|
|
| A442 |
BAY-1158061 Biosimilar(Anti-PRLR / Prolactin Receptor Reference Antibody)
Featured
|
|
|
| A443 |
Rolinsatamab Biosimilar(Anti-PRLR / Prolactin Receptor Reference Antibody)
Featured
|
Rolinsatamab is a IgG1κ type chimeric antibody targeting to PRLR (prolactin receptor). Rolinsatamab can be conjugated with pyrrolobenzodiazepine (PDB) dimer SGD-1882 (HY-101127) via a cleavable maleimidocaproyl type linker, to form an antibody-drug conjugate, Rolinsatamab talirine. One Rolinsatamab talirine has an average of 2 site-specific drug attachment engineered cysteines (C242, C242'). The linker equips the valine-alanine dipeptide, as cathepsine B cleavage site. on an average of 2 site-specific drug attachment engineered cysteines (C242, C242'). |
|
| A444 |
Forerunner patent anti-Prominin-1 Biosimilar(Anti-PROM1 / CD133 Reference Antibody)
Featured
|
|
|
| A445 |
AGS-1C4D4 Biosimilar(Anti-PSCA Reference Antibody)
Featured
|
|
|
| A446 |
Inclacumab Biosimilar(Anti-P-Selectin / CD62p Reference Antibody)
Featured
|
Inclacumab (Anti-Human selectin P Recombinant Antibody) is a human monoclonal IgG4 antibody selectively targets P-selectin with a Kd value of 9.9 nM. Inclacumab inhibits P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide bind with P-selectin with an IC50 value of 1.9 μg/mL and strongly inhibits cell adhesion. |
|
| A447 |
Neihulizumab Biosimilar(Anti-PSGL1 / CD162 Reference Antibody)
Featured
|
Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), leading to downregulation of activated T-cells. Neihulizumab can be uesd for steroid-refractory acute graft-versus-host-disease (SR-aGVHD), psoriasis, psoriatic arthritis and ulcerative colitis research. |
|
| A448 |
AG02-ADC Biosimilar(Anti-PTGFRN / CD315 Reference Antibody)
Featured
|
|
|
| A121 |
Ocrelizumab
Featured
|
|
|
| A115 |
Casirivimab Biosimilar
Featured
|
Casirivimab (REGN10933) is a human monoclonal antibody that targets the SARS-CoV-2 virus, which causes COVID-19. Casirivimab is ineffective against COVID-19 variants. Casirivimab can be used in combination with Imdevimab (HY-P99342), which alters the lung response of K18-hACE2 mice to the SARS-CoV-2 δ variant, effectively reducing viral load and improving symptoms. |
|
| A108 |
L19-TNF Biosimilar(Anti-Fibronectin Reference Antibody)
Featured
|
|
|
| A120 |
Imdevimab
Featured
|
Imdevimab (REGN10987) is a human monoclonal antibody to target SARS-CoV-2 virus, which causes COVID-19. Imdevimab lacks efficacy against COVID-19 variants. Imdevimab can be used in combination with Casirivimab (HY-P99341), it reduces viral load and improves diseases. |
|
